TRAIL and Wogonin Combination Therapy Demonstrates Potential in Prostate Cancer Treatment

Strategic Insights -

A recent study published in the British Journal of Pharmacology has shed light on a potential new approach to treating prostate cancer. Researchers at the University of Pittsburgh discovered that a combination of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and wogonin, a compound found in a Chinese herb, can trigger apoptosis in prostate cancer cells without harming normal cells. This synergistic interaction was found to be mediated by the up-regulation of p53 and Puma, which are proteins involved in DNA damage and repair.

Key Takeaways:

  • The combination of TRAIL and wogonin was found to trigger apoptosis in prostate cancer cells through the up-regulation of p53 and Puma.
  • This synergistic interaction was associated with DNA damage and reactive oxygen species (ROS) generation.
  • N-acetylcysteine (NAC), an antioxidant, inhibited ROS generation and the synergistic interaction between TRAIL and wogonin.
  • The study suggests that wogonin enhances TRAIL-induced cytotoxicity through the up-regulation of p53 and Puma, mediated by ROS.
  • Deficiency in either p53 or Puma prevented the enhancement of TRAIL-induced apoptosis by wogonin.
  • The researchers concluded that this combination therapy may be a potential new approach to treating prostate cancer.

Statistics:

  • The study involved the human prostate cancer cell line LNCaP, which was resistant to TRAIL.
  • The combination of TRAIL and wogonin was evaluated for evidence of synergy in triggering apoptosis.
  • Western blot assay and the 'comet' assay were used to study the underlying mechanisms of cell death.
  • The study demonstrated that p53-dependent Puma up-regulation played an important role in TRAIL-induced apoptosis.
  • The ROS generation was associated with up-regulation of p53 through DNA damage.

Sources:

  • "Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin." British Journal of Pharmacology, 2009;157(7):1189-1202.